thought leadership

Lyophilized products are on the rise: Here's what you need to know

There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug innovation and technological advancement in the lyophilization process as well as ease of access to outsourcing partners who specialize in the formulation development and manufacturing of lyophilized biological products. 

In this article, Emergent experts discuss the factors that are driving the demand of lyophilized products and what to consider when selecting a CDMO partner to support your drug manufacturing needs. 

Download Article

 

Factoring Stability in the Biologic Drug Mix

Jee Look, senior director of drug product development for Emergent BioSolutions recently contributed to an article in ...

READ MORE

Bloomberg: The Way Ahead

Emergent BioSolutions, a Wells Fargo Corporate & Investment Banking customer since 2011, helps governments respond to health...

READ MORE

EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic...

READ MORE